Surgery Partners (NASDAQ:SGRY) Downgraded to “Hold” Rating by Zacks Research

Posted by Francis Steltz on Aug 12th, 2026

Surgery Partners (NASDAQ:SGRY – Get Free Report) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

SGRY has been the topic of a number of other reports. Jefferies Financial Group reissued a “buy” rating and set a $17.00 price objective on shares of Surgery Partners in a report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Surgery Partners in a research report on Tuesday, May 26th. TD Cowen boosted their price target on Surgery Partners from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 price target on shares of Surgery Partners in a research note on Tuesday. Finally, Raymond James Financial set a $18.00 price objective on Surgery Partners in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.45.

Read Our Latest Report on Surgery Partners

Surgery Partners Stock Performance

Shares of Surgery Partners stock opened at $15.00 on Monday. The firm has a market capitalization of $1.96 billion, a P/E ratio of -21.43, a PEG ratio of 4.77 and a beta of 1.91. The company has a quick ratio of 1.69, a current ratio of 1.86 and a debt-to-equity ratio of 1.17. The company has a 50 day moving average price of $15.51 and a 200 day moving average price of $14.43. Surgery Partners has a 52 week low of $11.41 and a 52 week high of $24.10.

Surgery Partners (NASDAQ:SGRY – Get Free Report) last released its earnings results on Monday, August 10th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.04. Surgery Partners had a negative net margin of 2.63% and a positive return on equity of 0.87%. The company had revenue of $848.90 million for the quarter, compared to the consensus estimate of $830.03 million. During the same quarter in the previous year, the firm earned $0.17 EPS. Surgery Partners’s revenue was up 2.7% compared to the same quarter last year. Sell-side analysts expect that Surgery Partners will post 0.25 EPS for the current year.

Institutional Trading of Surgery Partners

Hedge funds and other institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC raised its holdings in shares of Surgery Partners by 3.8% during the fourth quarter. Janus Henderson Group PLC now owns 13,537,984 shares of the company’s stock worth $209,162,000 after purchasing an additional 501,401 shares during the last quarter. Pentwater Capital Management LP lifted its position in Surgery Partners by 66.9% during the third quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock valued at $252,777,000 after purchasing an additional 4,681,000 shares during the period. UBS Group AG boosted its holdings in Surgery Partners by 111.4% in the fourth quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock valued at $120,571,000 after purchasing an additional 4,113,052 shares during the last quarter. BlackRock Inc. purchased a new stake in Surgery Partners in the second quarter valued at $104,857,000. Finally, Dimensional Fund Advisors LP grew its position in Surgery Partners by 7.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 5,296,411 shares of the company’s stock worth $63,131,000 after purchasing an additional 389,831 shares during the period.

Surgery Partners News Roundup

Here are the key news stories impacting Surgery Partners this week:

Positive Sentiment: Q2 results beat expectations: Adjusted earnings were $0.10 per share versus the $0.06 consensus estimate, while revenue of $848.9 million exceeded the $830.0 million forecast. Revenue increased 2.7% year over year, and same-facility revenue rose 5.0%. Surgery Partners Q2 Earnings and Revenues Beat Estimates
Positive Sentiment: Full-year guidance was reaffirmed: Surgery Partners continues to expect 2026 revenue of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million, excluding the pending Idaho Falls divestiture. Management said the transaction should improve cash conversion and support deleveraging. Surgery Partners Announces Second Quarter Results
Positive Sentiment: Analyst support remains favorable: Cantor Fitzgerald reaffirmed its “overweight” rating and set an $18 price target. A separate brokerage consensus target was reported at $21.60, implying substantial potential upside from recent trading levels. Cantor Fitzgerald Reiterates Overweight Rating
Neutral Sentiment: Broader healthcare stocks could benefit if weak employment data increases expectations for Federal Reserve interest-rate cuts, although this is a sector-wide factor rather than a Surgery Partners-specific catalyst. Likely ETF and Stock Winners From July Jobs Report
Negative Sentiment: Profitability and cash generation weakened: Q2 net loss attributable to Surgery Partners widened to $15.0 million from $2.5 million a year earlier. Adjusted EBITDA declined to $125.2 million from $129.0 million, while operating cash flow fell to $59.3 million from $81.3 million. Net debt remained elevated at approximately 4.4 times EBITDA. Surgery Partners Reports Second Quarter Results

About Surgery Partners

(Get Free Report)

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.